1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
J. Li(Peking University), Lin Shen(Peking University), Yi Huang(Hubei Cancer Hospital), Yaojun Zhang(Sun Yat-sen University), Mei Shi(Xijing Hospital), Quanli Gao(Zhengzhou University), Ying Yuan(Zhejiang Cancer Hospital), Jing Xu(Chinese People's Liberation Army), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Ye Xu(Central South University of Forestry and Technology), Haiping Jiang(California Institute for Regenerative Medicine), Aimin Zang(Affiliated Hospital of Hebei University), Yunong Gao, Jing Wang(Shanxi Medical University), Kun Wang(Union Hospital), Dong Wang(Chongqing University), Tianshu Liu(Sun Yat-sen University), Hanguang Hu(Zhejiang University), Chunmei Shi(Fujian Medical University), Yanhong Deng(Sun Yat-sen University)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541